Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Probiotic Formulations for the Treatment and Alleviation of Metabolic and Oxidative Stress, Inflammation and Neurodegeneration

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Publication Date:
    November 28, 2024
  • معلومة اضافية
    • Document Number:
      20240390435
    • Appl. No:
      18/412561
    • Application Filed:
      January 14, 2024
    • نبذة مختصرة :
      Provided herein is a product comprising three bacterial strains that are Lactobacillus fermentum NCIMB 5221, Lactobacillus plantarum NCIMB 8826 and Bifidobacteria longum spp. infantis NCIMB 7022SS.
    • Assignees:
      Proviva Pharma Inc. (MONTREAL, CA)
    • Claim:
      1-12. (canceled)
    • Claim:
      13. A product comprising three bacterial strains that are Lactobacillus fermentum NCIMB 5221, Lactobacillus plantarum NCIMB 8826 and Bifidobacteria longum spp. infantis NCIMB 7022SS.
    • Claim:
      14. The product of claim 13, that is a prebiotic composition, wherein optionally the prebiotic composition comprises or consists of: a triphala, or any herbal rasayana formula consisting of relatively equal parts of three myrobalans, taken without seed: amalaka (Emblica officinalis), bibhitaki (Terminalia bellirica), and haritaki (Terminalia chebula), and optionally the triphala or the herbal rasayana-comprising formulation or pharmaceutical composition is an aqueous or water-based formulation, and optionally between about 0.5% and 50% of the product is the triphala or the herbal rasayana.
    • Claim:
      15. The product of claim 14, wherein the probiotic composition is alive or dead.
    • Claim:
      16. The product of claim 13, wherein the bacterial strains are: (a) each present in relatively equal proportions; (b) are each present at a total of between about 105 CFU/ml to 1011 CFU/ml, or between about 10s CFU/gm to between about 3.0×1011 CFU/gm, or (c) are each present at a total of between about 3.0×109 CFU/ml or about 3.0×109 CFU/gm,
    • Claim:
      17. The product of claim 13, wherein the bacterial strains are at relative proportions of: Lactobacillus fermentum NCIMB 5221 (Lf5221) at about 1.0×109 CFU/ml, Lactobacillus plantarum NCIMB 8826 (Lp8826) at about 1.0×109 CFU/ml, and Bifidobacteria longum spp. infantis NCIMB 702255 (BÏ702255) at about 1.0×109 CFU/ml.
    • Claim:
      18. The product of claim 1, manufactured or formulated in the form of a solution, a suspension, an emulsion, a powder, a lozenge, a pill, a syrup, a tablet, a capsule, a geltab, an aerosol, a suppository, a chewing gum, a capsule or a sachet.
    • Claim:
      19. The product of claim 1, manufactured or formulated as an edible material, drink or foodstuff, optionally comprising water, a fluid or solid dairy product, a milk, a condensed milk, a drinkable yogurt, a yogurt, a fermented beverage, an ice cream, a cheese, a soy milk, vegetable juice, a fruit juice, a sports drink, a dessert, a jelly, a candy, a baby food, a health food, a dietary supplement or an additive.
    • Current International Class:
      61; 23; 61; 61
    • الرقم المعرف:
      edspap.20240390435